JO
STLN

John Overdeck’s Starling Oncology STLN Stock Holding History

John Overdeck’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.63M Buy
668,839
+361,085
+117% +$1.52M ﹤0.01% 2451
2026
Q1 		$945K Buy
307,754
+45,704
+17% +$140K ﹤0.01% 3302
2025
Q4 		$933K Sell
262,050
-16,917
-6% -$62.7K ﹤0.01% 2964
2025
Q3 		$974K Buy
278,967
+802
+0.3% +$2.75K ﹤0.01% 2587
2025
Q2 		$570K Buy
+278,165
New +$695K ﹤0.01% 2527
2023
Q2 		– Sell
-42,775
Closed -$29K – 3261
2023
Q1 		$29K Sell
42,775
-7,717
-15% -$9.85K ﹤0.01% 2820
2022
Q4 		$83.3K Buy
+50,492
New +$142K ﹤0.01% 2533

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

John Overdeck's STLN Position: Q2 2026 in Review

John Overdeck increased its Starling Oncology (STLN) stake by 117% in Q2 2026, buying an estimated $1.52M and bringing the position to 668,839 shares worth $3.63M. The position accounts for ﹤0.01% of the portfolio, ranked #2451.

John Overdeck first reported a position in STLN in Q4 2022 and has held it in 7 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • John Overdeck held 668,839 shares of Starling Oncology worth $3.63M as of Q2 2026.
  • John Overdeck bought 361,085 Starling Oncology shares in Q2 2026, an estimated $1.52M.
  • Starling Oncology made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2451 holding.
  • John Overdeck first reported a position in Starling Oncology in Q4 2022 and has held it in 7 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.